Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Olema Pharmaceuticals Inc
(NQ:
OLMA
)
9.320
-0.520 (-5.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Olema Pharmaceuticals Inc
< Previous
1
2
3
Next >
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 08, 2024
Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) Near the Top of Equities by Percentage Gain on 2/1
February 01, 2024
Via
Investor Brand Network
Olema Oncology to Participate in Upcoming Investor Conferences in May
May 01, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/28
November 28, 2023
Via
Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/13
November 13, 2023
Via
Investor Brand Network
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
March 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/9
November 09, 2023
Via
Investor Brand Network
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/8
November 08, 2023
Via
Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/7
November 07, 2023
Via
Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 10/16
October 16, 2023
Via
Investor Brand Network
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
December 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences in November
November 01, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 22, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
October 17, 2023
Mr. Garland brings significant industry expertise with a long track record of successful launches
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 16, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
October 12, 2023
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From
Olema Oncology
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.